Savara Inc (NASDAQ:SVRA) has obtained expert guidance from the FDA on the clinical program requirements for a NDA filing for Molgradex, targeting autoimmune PAP. Depending on the received recommendations, the firm intend to modify the statistical analyses and endpoint order of its underway IMPALA study, for now enrolling subjects in Japan and Europe, to qualify the study as a key Phase 3 trial in the U.S.
The total count of subjects to be registered will increase to 90 from 51 so as to support the changed program. If successful, this trial would serve as the major trial for regulatory filing aiming marketing authorization of Molgradex in the U.S. in addition to Japan and Europe.
Rob Neville, who is the CEO of Savara, posted that since they acquired Molgradex last year, they have posted notable progress, and having a prospect to utilize existing IMPALA trial as a worldwide Phase 3 trial is a win for the firm. It gives an opportunity to expedite the approval of the offering by removing the need to carry out a separate Phase 3 trial.
This is promising update for the PAP community in the U.S., as they contemplate Molgradex can provide a game changing therapy targeting a disease where the standard treatment is to periodically carry out an invasive lung lavage course requiring general anesthesia.
Savara announced that the IMPALA trial is planned to evaluate the safety and efficiency of Molgradex with placebo in subjects with PAP. The trial started enrolling subjects in Japan and Europe last year, and aims to extend this enrollment so as to register 90 subjects by Q1 2018. So far, 50% of planned enrollment is completed. The company expects to announce top line report by Q4 2018.
In the last trading session, the stock price of gained almost 1% to close the session at $5.35.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.